atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorder treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorder treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA. The event will take place from March 3-5, 2025.
The company's management team will engage in a fireside chat scheduled for Monday, March 3 at 11:50 A.M. ET, along with one-on-one investor meetings. A webcast of the presentation will be available, with an archived replay accessible on the Investors section of atai's website under Events for up to 90 days.
Details
News Market Reaction – ATAI
The recorded move for ATAI in the trading session of this news was -5.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company’s participation:
Format: Fireside chat and 1x1 investor meetings
Date and Time: Fireside chat on Monday, March 3 at 11:50 A.M. ET
Webcast link: Here
An archived replay will be available on the Investors section of the atai website under Events for up to 90 days.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The Company was founded in response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to developing novel, evidence-based therapeutics to treat depression, anxiety and other mental health disorders. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
Contact Information
Investor Contact:
IR@atai.life
Media Contact:
PR@atai.life
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.